A Płużańska

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

Steffen Walter, Toni Weinschenk, Arnulf Stenzl, Romuald Zdrojowy et autres

de, pl, ch, it, jp (code pays fourni par la source)

Abstract 5365: Prolonged survival of patients with advanced renal cancer responding to multi-peptide vaccine IMA901 after single-dose cyclophosphamide

Steffen Walter, Toni Weinschenk, Arnulf Stenzl, Romuald Zdrojowy et autres

Abstract Translational research and the clinical development of therapeutic cancer vaccines requires stronger scientific rationalization. Here we demonstrate how immune response markers as well as biomarkers defining the immune regulatory environment were utilized as guiding tools from discovery to advanced clinical trials …

de, pl, ch, it, jp, us (code pays fourni par la source)

Randomized double-blind placebo-controlled international trial of abago-vomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: The Monoclonal Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abago-vomab (MIMOSA) trial.

Jacobus Pfisterer, J. S. Berek, Antonio Casado, Karel Cwiertka et autres

LBA5002 Background: Abagovomab, a murine monoclonal anti-idiotypic antibody directed against CA125, has been shown to induce an active immune response against CA125 tumor-associated antigen in advanced ovarian cancer patients. Methods: Abagovomab (A) has been tested in a randomized (2:1) double-blind, placebo (P) …

es (code pays fourni par la source)

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

Luca Gianni, Urania Dafni, Richard D. Gelber, Evandro de Azambuja et autres

it, gr, us, be, ch, de, gb, br, es, pl, ru, hr, cn, ca, au (code pays fourni par la source)

A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC).

P. Fidias, T. A. Ciuleanu, Oleg Gladkov, G. Manikhas et autres

LBA7007 Background: NOV-002 is a formulation of disodium glutathione disulfide (GSSG). GSSG is a naturally occurring substance that functions as a component of the glutathione (GSH) pathway, vital to the regulation of the intracellular redox state. A key function of the GSH/GSSG …

ru, pl, us (code pays fourni par la source)

Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial.

Paul Sabbatini, J. S. Berek, Antonio Casado, Karel Cwiertka et autres

5036 Background: Phase I/II data demonstrated that abagovomab, a murine monoclonal anti-idiotypic antibody against CA125, induces an active immune response against CA125 tumor-associated antigen (TAA). Methods: Abagovomab is evaluated in a randomized (2:1) double-blind, placebo-controlled, multicenter phase III trial in patients with …

A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer

E.H. Tan, Rodryg Ramlau, A Płużańska, H P Kuo et autres

BACKGROUND: Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed to identify genes with potential use as biomarkers for clinical …

sg, pl, tw, de, cn, es, bg, ru, ch (code pays fourni par la source)

Doxorubicin and Paclitaxel versus Fluorouracil, Doxorubicin and Cyclophosphamide as First-Line Therapy for Women with Advanced Breast Cancer: Long-Term Analysis of the Previously Published Trial

Jacek Jassem, Tadeusz Pieńkowski, A Płużańska, S. Jelić et autres

BACKGROUND: The aim of this study was to perform an independent review of the efficacy data and to determine whether the efficacy difference observed in a phase III randomised clinical trial that compared doxorubicin plus paclitaxel (AT) versus fluorouracil/doxorubicin/cyclophosphamide (FAC) in first-line …

pl, rs, lv, hu, it, be (code pays fourni par la source)

PharmaNews · PharmaTicker

Gϋnter von Minckwitz, Mattea Linder, Sibylle Loibl, Paraskevi Savvari et autres

Contents of Forthcoming Issues · Themenvorschau

Gϋnter von Minckwitz, Mattea Linder, Sibylle Loibl, Paraskevi Savvari et autres

Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer

David Cunningham, Bhawna Sirohi, A Płużańska, B. Utracka-Hutka et autres

gb, pl, au, tw, cn, fr (code pays fourni par la source)

Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment

Kathy S. Albain, Shona Nag, G. Calderillo-Ruiz, Johann Petrus Jordaan et autres

PURPOSE: The objective of this phase III global study was to compare the efficacy of gemcitabine plus paclitaxel (GT) versus paclitaxel in patients with advanced breast cancer. It was designed as a pivotal study for the approval of G for a breast …

es (code pays fourni par la source)